Trial Profile

Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Ramucirumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms RamAtezo-1

Most Recent Events

29 Apr 2024 Status changed from active, no longer recruiting to completed.
01 Nov 2022 Results published in the Lung Cancer.
10 Aug 2022 Planned End Date changed from 2 Nov 2023 to 25 Apr 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com